BIO-IMAGING TECHNOLOGIES, INC. AND BESSELAAR ASSOCIATES SIGN WORLDWIDE CO-MARKETING AGREEMENT

WEST TRENTON, N.J., Aug. 29 /PRNewswire/ — Bio-Imaging Technologies, Inc. (Nasdaq Small Cap: BITI), and Besselaar Associates, a unit of Corning Incorporated (NYSE: GLW) announced today that they have signed an agreement which permits Besselaar to exclusively co-market Bio-Imaging’s core laboratory services and Bio-Imaging’s Bio/ImageBase(TM) software product for computerized regulatory submission of medical imaging data. The agreement also permits Bio-Imaging to exclusively co-market the services of Besselaar to Bio-Imaging Technologies’ clients and prospects.

As part of this agreement, Besselaar’s direct parent, Corning Pharmaceutical Services Inc., made an immediate $500,000 loan with limited recourse to Bio-Imaging Technologies.

In addition, Corning Pharmaceutical Services Inc. may, at its option on September 30, 1994, acquire, over time, up to an approximate 46 percent equity interest in Bio-Imaging Technologies represented by capital stock and warrants for approximately $2,500,000. In the event Corning Pharmaceutical Services Inc. exercises its option to the full extent, Besselaar shall pay to Bio-Imaging Technologies a fee pursuant to the terms of the exclusive co-marketing agreement. Bio-Imaging has agreed not to issue any additional equity until after September 30, 1994.

Terrence P. Brennan, President and Chief Executive Officer of Bio- Imaging Technologies, said, “With this agreement, Bio-Imaging will immediately broaden its marketing exposure in the U.S. and can now pursue business opportunities in Europe and Japan. In addition, Bio- Imaging Technologies can more rapidly develop and test several proprietary applications of its medical imaging technology.”

“Besselaar will be the only contract research organization able to offer Bio-Imaging Technologies’ medical imaging products,” said Dr. Brian Firth, Executive Vice President and Chief Operating Officer of Besselaar U.S.A. “These products will improve data quality, accelerate the development process and help our clients get their products to market sooner.”

Bio-Imaging Technologies, Inc. is an emerging leader in providing medical image processing and digital image management services for pharmaceutical and medical device development. In addition, Bio-Imaging markets a desktop computer software product, Bio/ImageBase(TM), for digital management and regulatory submission of medical imaging data.

Besselaar Associates provides clinical drug development services to the pharmaceutical and biotechnology industries. It is the largest firm of its kind, with 16 offices located in the U.S., Europe and the Pacific Rim. These services include clinical plan design, clinical trials management, biostatistical services and regulatory consulting on a worldwide basis. Besselaar is owned by Corning Life Sciences Inc. (CLSI) through CLSI’s Corning Pharmaceutical Services Inc. subsidiary.

/delval/

-0- 8/29/94

/CONTACT: William L. Robbins, Vice President, Business Development, or Robert J. Phillips, Investor Relations, both of Bio-Imaging, 609-883-2000, or Mark DiIanni, Sr. Vice President, Business Development, of Besselaar Associates, 609-452-8550, or Richard B. Klein, investor relations of Corning, 607-974-8313/

(BITI GLW)

CO: Bio-Imaging Technologies, Inc.; Besselaar Associates ST: New

Jersey IN: CPR Cardiopulmonary Resuscitation (CPR)

Incoming search terms:

  • Bio-Imaging Technologies Inc mail